Latest Ratios: P/E Ratio 20.3x · EV/EBITDA 13.6x · ROE 9.3%. (2007–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $2.0B | $2.2B | $1.5B | $1.6B | $1.5B | $1.9B | $1.4B | $891M | $405M | $404M |
| Enterprise Value | $2.1B | $2.1B | $2.4B | $1.6B | $1.7B | $1.6B | $2.0B | $1.4B | $838M | $394M | $421M |
| P/E Ratio → | 20.34 | 20.61 | 29.63 | 24.24 | 35.03 | 33.28 | 56.29 | 54.93 | 51.04 | 29.74 | 33.70 |
| P/S Ratio | 1.39 | 1.39 | 1.89 | 1.43 | 1.69 | 1.74 | 2.44 | 2.14 | 1.72 | 0.95 | 1.01 |
| P/B Ratio | 1.80 | 1.83 | 2.24 | 2.14 | 2.54 | 2.62 | 3.60 | 2.91 | 3.23 | 2.31 | 2.54 |
| P/FCF | 19.04 | 19.09 | 19.74 | 14.73 | 16.63 | 43.11 | 18.21 | 187.24 | 31.99 | 8.24 | — |
| P/OCF | 17.72 | 17.77 | 18.71 | 13.49 | 15.32 | 38.04 | 17.08 | 115.25 | 26.83 | 7.67 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.48 | 2.04 | 1.53 | 1.80 | 1.85 | 2.57 | 2.09 | 1.62 | 0.93 | 1.05 |
| EV / EBITDA | 13.56 | 13.60 | 20.24 | 15.46 | 20.63 | 19.85 | 34.71 | 29.89 | 26.63 | 12.34 | 19.03 |
| EV / EBIT | 15.17 | 15.38 | 21.97 | 17.58 | 24.72 | 24.12 | 43.49 | 37.35 | 32.96 | 14.78 | 23.07 |
| EV / FCF | — | 20.31 | 21.31 | 15.81 | 17.64 | 45.83 | 19.14 | 183.14 | 30.08 | 8.02 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.5% | 32.5% | 32.5% | 32.1% | 31.5% | 31.2% | 29.6% | 27.6% | 26.7% | 27.2% | 26.5% |
| Operating Margin | 9.7% | 9.7% | 8.9% | 8.6% | 7.2% | 7.6% | 5.8% | 5.4% | 4.4% | 5.9% | 3.9% |
| Net Profit Margin | 6.7% | 6.7% | 6.4% | 5.9% | 4.8% | 5.2% | 4.3% | 3.9% | 3.4% | 3.2% | 3.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.3% | 9.3% | 8.8% | 9.3% | 7.6% | 8.3% | 6.7% | 6.7% | 7.8% | 8.1% | 8.0% |
| ROA | 6.7% | 6.7% | 6.0% | 6.4% | 4.9% | 4.9% | 4.3% | 5.1% | 5.6% | 5.5% | 5.7% |
| ROIC | 8.8% | 8.8% | 7.9% | 8.8% | 7.4% | 7.7% | 6.3% | 7.8% | 8.9% | 11.1% | 7.3% |
| ROCE | 10.9% | 10.9% | 9.6% | 10.8% | 8.4% | 8.4% | 6.9% | 8.2% | 9.0% | 12.7% | 9.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.19 | 0.28 | 0.25 | 0.28 | 0.46 | 0.46 | 0.17 | 0.06 | 0.25 | 0.16 |
| Debt / EBITDA | 1.35 | 1.35 | 2.35 | 1.67 | 2.15 | 3.28 | 4.24 | 1.80 | 0.55 | 1.35 | 1.13 |
| Net Debt / Equity | — | 0.12 | 0.18 | 0.16 | 0.15 | 0.16 | 0.18 | -0.06 | -0.19 | -0.06 | 0.11 |
| Net Debt / EBITDA | 0.82 | 0.82 | 1.50 | 1.05 | 1.18 | 1.18 | 1.67 | -0.67 | -1.69 | -0.34 | 0.77 |
| Debt / FCF | — | 1.22 | 1.58 | 1.07 | 1.01 | 2.72 | 0.92 | -4.09 | -1.91 | -0.22 | — |
| Interest Coverage | 14.30 | 14.30 | 13.85 | 8.32 | 7.76 | 11.40 | 14.15 | 11.68 | 5.07 | 5.96 | 7.83 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.80 | 1.80 | 1.67 | 1.38 | 1.70 | 2.76 | 2.00 | 3.08 | 2.86 | 2.98 | 2.64 |
| Quick Ratio | 1.80 | 1.80 | 1.67 | 1.38 | 1.70 | 2.76 | 2.00 | 3.08 | 2.86 | 2.98 | 2.64 |
| Cash Ratio | 0.55 | 0.55 | 0.63 | 0.45 | 0.61 | 1.44 | 1.01 | 1.28 | 1.14 | 1.03 | 0.16 |
| Asset Turnover | — | 0.99 | 0.82 | 1.03 | 1.01 | 0.91 | 0.86 | 1.02 | 1.46 | 1.59 | 1.73 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 38.92 | 42.76 | 40.02 | 48.42 | 61.67 | 64.20 | 86.21 | 70.85 | 80.19 | 107.26 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.9% | 4.9% | 3.4% | 4.1% | 2.9% | 3.0% | 1.8% | 1.8% | 2.0% | 3.4% | 3.0% |
| FCF Yield | 5.3% | 5.2% | 5.1% | 6.8% | 6.0% | 2.3% | 5.5% | 0.5% | 3.1% | 12.1% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $18M | $17M | $16M | $16M | $16M | $16M | $14M | $13M | $12M | $12M |
Medicaid reimbursement rate sensitivity
Based on current market data, ADUS trades at a forward P/E of 13.87, which appears to reflect a valuation discount relative to broader healthcare services peers, suggesting that investors are pricing in the regulatory risks inherent in its Medicaid-heavy revenue model despite consistent double-digit top-line expansion.
The PEG ratio of 0.92 indicates that the market may be undervaluing the company's growth trajectory relative to its earnings potential. This valuation suggests a defensive posture, as the market treats the company as a utility-like provider rather than a high-growth clinical operator.
According to historical financial data, ROIC has remained range-bound between 2.0% and 2.7% over the last ten quarters, indicating that the company's aggressive inorganic growth strategy has yet to yield a meaningful improvement in the compounding of returns on invested capital.
The persistent low ROIC suggests that the capital deployed for tuck-in acquisitions is largely maintaining the existing business scale rather than driving superior economic profit. Investors should monitor whether the integration of recent acquisitions can eventually lift these returns above the company's cost of capital.
As reported in quarterly filings, asset turnover has remained stagnant near 0.25, reflecting the capital-intensive nature of managing a decentralized caregiver workforce and the inherent friction in collecting payments from state-level Medicaid programs across diverse geographic jurisdictions.
The stability of DSO around 35-37 days highlights the company's reliance on state payors, where payment cycles are often subject to legislative budget impasses. This efficiency profile suggests that operational leverage is difficult to achieve without significant improvements in the speed of cash collection.
Based on the most recent balance sheet, the current ratio of 1.83 provides a sufficient liquidity cushion to navigate the cyclical payment delays typical of the Medicaid-funded personal care sector, ensuring that the company maintains operational continuity even during periods of state-level fiscal stress.
The absence of significant short-term debt obligations, combined with a healthy current ratio, suggests that the company is well-positioned to fund its ongoing tuck-in acquisition strategy. This liquidity profile is essential for mitigating the risks associated with the company's high-volume, low-margin business model.
Analysts frequently misapply standard operating margin benchmarks to ADUS, failing to account for the fact that the company's profitability is structurally capped by state-mandated reimbursement rates rather than competitive pricing power, which obscures the true underlying efficiency of its caregiver recruitment engine.
Focusing solely on operating margins ignores the 'wage pass-through' dynamics that define this industry. A more appropriate metric for assessing the company's health would be the 'Caregiver Retention Rate' or 'Billable Hours per Business Day,' which better capture the operational reality of the business.
Includes 30+ ratios · 19 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADUS stock.
Addus HomeCare Corporation's current P/E ratio is 20.3x. The historical average is 29.5x. This places it at the 20th percentile of its historical range.
Addus HomeCare Corporation's current EV/EBITDA is 13.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 16.6x.
Addus HomeCare Corporation's return on equity (ROE) is 9.3%. The historical average is 7.9%.
Based on historical data, Addus HomeCare Corporation is trading at a P/E of 20.3x. This is at the 20th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Addus HomeCare Corporation has 32.5% gross margin and 9.7% operating margin.
Addus HomeCare Corporation's Debt/EBITDA ratio is 1.3x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.